Science Daily22h
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Armed robbery in Revesby10h
First-Ever Drug Cuts Heart Attacks, Strokes in Diabetes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Daily13h
Dapagliflozin prevents renal injury by improving mitochondrial function and reducing oxidative stress in diabetes patients: Study
China: A recent study published in the Journal of Diabetes and its Complications highlighted dapagliflozin's (DAPA) ...
Breakthrough medication significantly cuts risk of heart attacks and strokes: Lancet study
A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...
gastroenterologyadvisor1h
SGLT-2 Inhibitors Reduce Liver Cirrhosis Risk in Type 2 Diabetes
SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.
gastroenterologyadvisor1h
Age Differences Seen in Efficacy of Type 2 Diabetes Treatments
HealthDay News — Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in the Journal of the American Medical Association.